HighField Biopharmaceuticals to Present Preclinical Data of HFG1, a Unique mRNA-based GLP-1R AgonistGLP-1R Agonist, for Treatment of Diabetes, at ADA’s 84th Scientific Sessions

21 May 2024
www.biospace.com
ImmunotherapyClinical Study
Filing of a U.S. IND for HFG1 is scheduled for Q3/2024 HANGZHOU, China--(BUSINESS WIRE)-- HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer, diabetes and other diseases, announced today that its abstract of preclinical data evaluating an mRNA-based GLP-1R agonist (HFG1) in diabetic monkeys has been accepted for a poster presentation at the American Diabetes Association (ADA) 84th Scientific Sessions June 21-24, 2024, in Orlando, FL. The abstract also will be published on the website of the ADA’s journal Diabetes. “We are very excited to introduce our unique lipid nanoparticle (LNP)-mRNA complex, HFG1, to the thousands of clinicians and researchers attending this year’s Scientific Sessions from around the world,” said HighField CEO and Scientific Founder Yuhong Xu, Ph.D. “The components of HFG1’s LNP complex were designed to provide consistent expression of a GLP-1R agonistGLP-1R agonist for diabetes and weight loss. We believe HFG1 will require far fewer injections than existing GLP-1 products while providing steady-state agonist activity.” Abstract Title: Preliminary Study of Efficacy and Duration of an mRNA-Based GLP-1R AgonistGLP-1R Agonist in Diabetic Monkeys. (Poster presentation number 1860-LB in category 12-B Clinical Therapeutics-Incretin-Based Therapies). Presenter: Dr. Yuhong Xu, HighField CEO Presentation: Saturday, June 22, 2024, 12:30 pm – 1:30 pm EDT (The poster will be displayed Saturday, Sunday and Monday in the Poster Hall; and at a Networking Reception Friday evening.) About HighField Biopharmaceuticals HighField is a clinical stage company focused on novel applications of liposome constructs to disrupt existing immuno-oncology and other disease technologies. The company also has a research and development center and a GMP-compliant production facility. HighField’s lead clinical development program is HF1K16, a drug encapsulated immune modulating liposome containing all-trans retinoic acid targeting myeloid-derived suppressor cells for treatment of solid tumors. The company’s pipeline also includes drug encapsulated immunoliposomes for solid tumor cancers and lipid therapeutics for gene delivery and gene therapy. For more information visit . View source version on businesswire.com: Contacts Media Contact: Dan Eramian Opus Biotech Communications danieleramian@comcast.net 425-306-8716 Business Development Contact: Donald Wyatt HighField Biopharmaceuticals dwyatt@hf-biopharm.com 206-356-8196 Source: HighField Biopharmaceuticals View this news release online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.